Home Alzheimer’s Disease Frontline Nivolumab/Ipilimumab with Limited Chemo Derives OS Benefit in NSCLC

Frontline Nivolumab/Ipilimumab with Limited Chemo Derives OS Benefit in NSCLC

Overall survival (OS) benefit derived from frontline treatment with nivolumab (Opdivo) plus ipilimumab (Yervoy) combined with 2 cycles of platinum-doublet chemotherapy in patients with  metastatic or recurrent non-small cell lung cancer (NSCLC), was further improved after at least 12 months of follow-up, according to results from the phase III CheckMate-9LA trial presented at the 2020 ASCO Virtual Scientific Program.1

“CheckMate 9LA met its primary end point of overall survival at the pre-planned interim analysis…With early separation of overall survival cureves and lower progressive disease rates as best overall response, the hypothesis for (this study) design was validated,” Martin Reck, MD, PhD, head of the department of thoracic oncology at Lung Clinic Grosshansdorf, said during a presentation of the results. 

The trial found that nivolumab plus ipilimumab combined with…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Recent Comments